Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open-Label, Multi-Center Study Evaluating the Efficacy, Safety and Pharmacokinetics of Genz-112638 in Gaucher Type 1 Patients

Next Previous
Trial Profile

A Phase 2, Open-Label, Multi-Center Study Evaluating the Efficacy, Safety and Pharmacokinetics of Genz-112638 in Gaucher Type 1 Patients

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eliglustat (Primary)
  • Indications Gaucher's disease type I
  • Focus Therapeutic Use
  • Sponsors Genzyme Corporation

Most Recent Events

  • 04 Dec 2018 Results analyzing bone mineral density T- and Z-scores and occurrence of bone pain and bone crises in 4 clinical trials (NCT00358150, NCT00891202, NCT00943111, and NCT01074944) presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
  • 04 Dec 2018 Results of long term pooled safety analysis (n=393) of ENGAGE, ENCORE, EDGE and this study presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
  • 31 Jan 2018 According to a Genzyme Corporation media release, data form the study will be presented at the 14thAnnual WORLDSymposium.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top